Drugs / Tenatumomab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02602067 | Nov 2015 → Apr 2017 | breast neoplasm, connective and soft tissue neoplasm, head and neck neoplasm, non-Hodgkin lymphoma +4 | sigma-tau i.f.r. S.p.A. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenatumomab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02602067 ↗ |
| Known as | Tenatumomab/ST2146 | “Tenatumomab/ST2146” NCT02602067 ↗ |
| Modality | Monoclonal antibody | “It is a murine monoclonal antibody directed towards Tenascin-C.” NCT02602067 ↗ |
| Route | Intravenous | “i.v. infused 131I-Tenatumomab” NCT02602067 ↗ |
| Target | TNC | “directed towards Tenascin-C” NCT02602067 ↗ |